NEW YORK (GenomeWeb) — Evotec and Indivumed announced today that they have partnered to discover and develop new precision therapeutics for colorectal cancer.
Under the terms of the two-year alliance, the Hamburg, Germany-based companies will apply Evotec's PanHunter bioinformatics analysis platform and drug discovery technologies to a colorectal cancer cohort from Indivumed's IndivuType database, which integrates patients' clinical information with genomic, transcriptomic, proteomic, and digital histopathology data derived from biospecimens.
In exchange for access to the cohort, Evotec made an undisclosed payment to Indivumed. Both firms will contribute to data analysis, target identification and validation, and drug discovery efforts, but Evotec will be responsible for partnering and programs and platforms resulting from the collaboration.
Additional terms were not disclosed.
"The access to IndivuType will allow us to identify targets that are matched to CRC subpopulations [that] have been categorized due to molecular phenotypes and are thus expected to deliver more effective and durable drugs," Evotec CSO Cord Dohrmann said in a statement.